Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  NOV 21  CAS patent coverage to include exemplified prophetic
                  substances identified in English-, French-, German-,
                  and Japanese-language basic patents from 2004-present
 NEWS  3  NOV 26  MARPAT enhanced with FSORT command
 NEWS  4  NOV 26  CHEMSAFE now available on STN Easy
 NEWS  5  NOV 26  Two new SET commands increase convenience of STN
                  searching
 NEWS  6  DEC 01  ChemPort single article sales feature unavailable
 NEWS  7  DEC 12  GBFULL now offers single source for full-text
                  coverage of complete UK patent families
 NEWS  8  DEC 17  Fifty-one pharmaceutical ingredients added to PS
 NEWS  9  JAN 06  The retention policy for unread STNmail messages
                  will change in 2009 for STN-Columbus and STN-Tokyo
 NEWS 10  JAN 07  WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
                  Classification Data
 NEWS 11  FEB 02  Simultaneous left and right truncation (SLART) added
                  for CERAB, COMPUAB, ELCOM, and SOLIDSTATEM
 NEWS 12  FEB 02  GENBANK enhanced with SET PLURALS and SET SPELLING

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* STN  Columbus  \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:44:01 ON 02 FEB 2009

=>
```

Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 11:44:15 ON 02 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JAN 2009 HIGHEST RN 1098270-10-0
DICTIONARY FILE UPDATES: 30 JAN 2009 HIGHEST RN 1098270-10-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10576267.str





chain nodes :
12 14
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
5-12 7-12 11-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11
exact/norm bonds :
3-4 4-5 5-12 7-12 11-14
exact bonds :
1-2 1-5 2-3
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11
isolated ring systems :
containing 1 : 6 :

G1:A,Ak,NH,CO2H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS
L1 STR



G1 A,Ak,NH,CO2H

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 11:44:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       99 TO ITERATE

100.0% PROCESSED       99 ITERATIONS                              38 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1384 TO     2576
PROJECTED ANSWERS:             391 TO     1129

L2           38 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 11:44:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1847 TO ITERATE

100.0% PROCESSED     1847 ITERATIONS                             675 ANSWERS
SEARCH TIME: 00.00.01

L3          675 SEA SSS FUL L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              185.88     186.10

FILE 'HCAPLUS' ENTERED AT 11:44:51 ON 02 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 2 Feb 2009 VOL 150 ISS 6
FILE LAST UPDATED: 1 Feb 2009 (20090201/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4 43 L3

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.40	197.50

FILE 'REGISTRY' ENTERED AT 11:47:30 ON 02 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JAN 2009 HIGHEST RN 1098270-10-0
DICTIONARY FILE UPDATES: 30 JAN 2009 HIGHEST RN 1098270-10-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10576267a.str



```
chain nodes :
12  15  16  17  18
ring nodes :
1  2  3  4  5  6  7  8  9  10  11
chain bonds :
5-12  7-12  11-15  15-16  15-18  16-17
ring bonds :
1-2  1-5  2-3  3-4  4-5  6-7  6-11  7-8  8-9  9-10  10-11
exact/norm bonds :
3-4  4-5  5-12  7-12  11-15  15-16  16-17
exact bonds :
1-2  1-5  2-3  15-18
normalized bonds :
6-7  6-11  7-8  8-9  9-10  10-11
isolated ring systems :
containing 1 : 6 :


G1:A,Ak,NH,CO2H

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS



L5      STRUCTURE UPLOADED

=> d 15
L5 HAS NO ANSWERS
L5              STR
```




```
G1 A,Ak,NH,CO2H
```

Structure attributes must be viewed using STN Express query preparation.

```
=> s l5
SAMPLE SEARCH INITIATED 11:47:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        4 TO ITERATE

100.0% PROCESSED        4 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:             4 TO      200
PROJECTED ANSWERS:                3 TO      163

L6            3 SEA SSS SAM L5

=> s l5 sss full
FULL SEARCH INITIATED 11:47:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      124 TO ITERATE

100.0% PROCESSED      124 ITERATIONS                               62 ANSWERS
SEARCH TIME: 00.00.01

L7           62 SEA SSS FUL L5

=>
Uploading C:\Program Files\Stnexp\Queries\10576267b.str
```



```
chain nodes :
12  15  16  17  18  19
ring nodes :
1  2  3  4  5  6  7  8  9  10  11
chain bonds :
5-12  7-12  11-15  15-16  15-18  16-17  16-19
ring bonds :
1-2  1-5  2-3  3-4  4-5  6-7  6-11  7-8  8-9  9-10  10-11
exact/norm bonds :
3-4  4-5  5-12  7-12  11-15  15-16  16-17  16-19
exact bonds :
1-2  1-5  2-3  15-18
normalized bonds :
6-7  6-11  7-8  8-9  9-10  10-11
isolated ring systems :
containing 1 : 6 :


G1:A,Ak,NH,CO2H
```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS

L8 STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8 STR



G1 A,Ak,NH,CO2H

Structure attributes must be viewed using STN Express query preparation.

=> s l8
SAMPLE SEARCH INITIATED 11:49:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3 TO 163
PROJECTED ANSWERS: 0 TO 0

L9 0 SEA SSS SAM L8

=> s l8 sss full
FULL SEARCH INITIATED 11:50:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 42 TO ITERATE

100.0% PROCESSED 42 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

L10 3 SEA SSS FUL L8

=> FIL HCAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 372.72 570.22

FILE 'HCAPLUS' ENTERED AT 11:50:10 ON 02 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Feb 2009 VOL 150 ISS 6
FILE LAST UPDATED: 1 Feb 2009 (20090201/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d his

(FILE 'HOME' ENTERED AT 11:44:01 ON 02 FEB 2009)

FILE 'REGISTRY' ENTERED AT 11:44:15 ON 02 FEB 2009
L1 STRUCTURE UPLOADED
L2 38 S L1
L3 675 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 11:44:51 ON 02 FEB 2009
L4 43 S L3

FILE 'REGISTRY' ENTERED AT 11:47:30 ON 02 FEB 2009
L5 STRUCTURE UPLOADED
L6 3 S L5
L7 62 S L5 SSS FULL
L8 STRUCTURE UPLOADED
L9 0 S L8
L10 3 S L8 SSS FULL

FILE 'HCAPLUS' ENTERED AT 11:50:10 ON 02 FEB 2009

=> s l7
L11 4 L7

=> s l10

L12 4 L10

=> d 111 ibib abs hitstr tot

L11 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:259908 HCAPLUS
DOCUMENT NUMBER: 146:309313
TITLE: Use of aminoarylthiazole and aminoaryloxazole dual c-kit/FGFR3 inhibitors for treating multiple myeloma
INVENTOR(S): Moussy, Alain; Kinet, Jean-Pierre
PATENT ASSIGNEE(S): Ab Science, Fr.
SOURCE: PCT Int. Appl., 31pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007026251	A2	20070308	WO 2006-IB3111	20060713
WO 2007026251	A3	20070712		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1904065	A2	20080402	EP 2006-820848	20060713
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20080207572	A1	20080828	US 2008-995592	20080114
PRIORITY APPLN. INFO.:			US 2005-698937P	P 20050714
			WO 2006-IB3111	W 20060713

OTHER SOURCE(S): MARPAT 146:309313
AB The invention relates to a method for treating Multiple Myeloma, FGFR3+ myeloma, especially relapsed or refractory multiple myeloma (4/14) expressing FGFR3, comprising administering a dual c-kit/FGFR3 inhibitor, e.g. 2-aminoarylthiazoles and 2-aminoaryloxazoles.
IT 928298-11-7 928298-14-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminoarylthiazole and aminoaryloxazole dual c-kit/FGFR3 inhibitors for treatment of multiple myeloma)
RN 928298-11-7 HCAPLUS
CN Benzamide, N-[3-[[5-(4-cyanophenyl)-2-oxazolyl]amino]-4-methylphenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 928298-14-0 HCAPLUS
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)-, mixt. with N-[3-[[5-(4-cyanophenyl)-2-oxazolyl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide (CA INDEX NAME)

CM 1

CRN 928298-11-7
CMF C25 H17 F3 N4 O2



CM 2

CRN 50-02-2
CMF C22 H29 F O5

Absolute stereochemistry.



L11 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:395287 HCAPLUS
DOCUMENT NUMBER: 142:447205
TITLE: Preparation of 2-(arylamino)oxazole derivatives as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3
INVENTOR(S): Moussy, Alain; Wermuth, Camille; Grierson, David; Benjahad, Abdellah; Croisy, Martine; Ciufolini, Marco; Giethlen, Bruno
PATENT ASSIGNEE(S): Science AB, Fr.; Centre National de la Recherche Scientifique CNRS; Institut Curie
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040139	A2	20050506	WO 2004-IB3698	20041022
WO 2005040139	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004283162	A1	20050506	AU 2004-283162	20041022
CA 2542909	A1	20050506	CA 2004-2542909	20041022
EP 1684750	A2	20060802	EP 2004-791783	20041022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015467	A	20061219	BR 2004-15467	20041022
JP 2007509130	T	20070412	JP 2006-536215	20041022
CN 1950347	A	20070418	CN 2004-80037159	20041022
US 20070142390	A1	20070621	US 2006-576267	20060418
IN 2006DN02206	A	20070420	IN 2006-DN2206	20060421

MX 2006004581	A	20061120	MX 2006-4581		20060424
NO 2006002308	A	20060522	NO 2006-2308		20060522
KR 2006118500	A	20061123	KR 2006-710034		20060523
PRIORITY APPLN. INFO.:			US 2003-513214P	P	20031023
			WO 2004-IB3698	W	20041022

OTHER SOURCE(S): CASREACT 142:447205; MARPAT 142:447205

GI



I



II

AB Title compds. I [R1, R2, R3, and R4 independently = H, halo, alkyloxy, etc.; R5 = H, (un)substituted linear or branched alkyl, COR8, etc.; R6 and R7 independently = H, halo, (un)substituted aryl, etc.; R8 = (un)substituted-aryl, -alkyl, -heteroaryl, etc.; R9 and/or R10 = H, (un)substituted-alkyl, -aryl, etc.; X = (un)substituted-alkyl, C:OY, NR9R10, etc.; Y = NR9R10, NHR9R10, (un)substituted-aryl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors. Thus, e.g., 3-acetyl-pyridine was brominated and subsequently converted into the azido derivative, which was cyclized with 2-methyl-5-nitrophenyl isocyanate followed by a reduction to the resp. amine derivative, which could be further elaborated to give II. The activity of I was evaluated in tyrosine kinase inhibition assays and it revealed that selected compds. of the invention possessed IC50 values of less than 1 μM. I should prove useful in the treatment of neoplastic diseases. Pharmaceutical compns. comprising I are disclosed.

IT 851317-91-4P 851318-09-7P 851318-20-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-(arylamino)oxazole derivs. as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3)

RN 851317-91-4 HCAPLUS
CN Benzamide, 3-(dimethylamino)-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-09-7 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 851318-20-2 HCAPLUS
CN 1-Piperazineacetamide, N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



IT 851317-75-4P 851317-76-5P 851317-77-6P
851317-78-7P 851317-79-8P 851317-80-1P

851317-81-2P 851317-82-3P 851317-83-4P
851317-84-5P 851317-85-6P 851317-88-9P
851317-90-3P 851317-92-5P 851317-93-6P
851317-94-7P 851317-95-8P 851317-96-9P
851317-97-0P 851317-98-1P 851317-99-2P
851318-00-8P 851318-01-9P 851318-02-0P
851318-03-1P 851318-04-2P 851318-05-3P
851318-06-4P 851318-07-5P 851318-08-6P
851318-10-0P 851318-11-1P 851318-12-2P
851318-13-3P 851318-14-4P 851318-15-5P
851318-16-6P 851318-17-7P 851318-18-8P
851318-19-9P 851318-21-3P 851318-22-4P
851318-23-5P 851318-24-6P 851318-25-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(arylamino)oxazole derivs. as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3)

RN 851317-75-4 HCAPLUS
CN Acetamide, N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-76-5 HCAPLUS
CN Acetamide, 2-cyano-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-77-6 HCAPLUS

CN Acetamide, 2-ethoxy-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-78-7 HCAPLUS
CN Propanamide, 3-methoxy-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-79-8 HCAPLUS
CN Urea, N-(4-methylphenyl)-N'-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-80-1 HCAPLUS
CN Urea, N-(4-cyanophenyl)-N'-[4-methyl-3-[[5-(3-pyridinyl)-2-

oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-81-2 HCAPLUS
CN Urea, N-(4-fluorophenyl)-N'-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-82-3 HCAPLUS
CN Urea, N-(2-fluorophenyl)-N'-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-83-4 HCAPLUS
CN Urea, N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851317-84-5 HCAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-85-6 HCAPLUS
CN Urea, N-[4-methyl-3-[(5-phenyl-2-oxazolyl)amino]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851317-88-9 HCAPLUS
CN 5-Oxazoleacetic acid, 2-[[2-methyl-5-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]amino]-, ethyl ester (CA INDEX NAME)



RN 851317-90-3 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-92-5 HCAPLUS
CN Benzamide, 3-bromo-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-93-6 HCAPLUS
CN Benzamide, N-[4-methoxy-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 851317-94-7 HCAPLUS
CN Benzamide, 4-[[3-(dimethylamino)propyl]amino]-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 851317-95-8 HCAPLUS
CN Benzamide, N-[4-fluoro-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 851317-96-9 HCAPLUS
CN 1H-Indole-6-carboxamide, N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-97-0 HCAPLUS
CN Benzamide, 3-(1-methylethoxy)-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-98-1 HCAPLUS
CN Benzamide, N-[4-methyl-3-[[5-(2-pyridinyl)-2-oxazolyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 851317-99-2 HCAPLUS
CN Benzamide, 3,5-dimethoxy-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-00-8 HCAPLUS
CN Benzamide, N-[3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 851318-01-9 HCAPLUS
CN Benzamide, N-[4-methyl-3-[(5-phenyl-2-oxazolyl)amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 851318-02-0 HCAPLUS
CN Benzamide, 3-fluoro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-03-1 HCAPLUS
CN Benzamide, N-[4-chloro-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 851318-04-2 HCAPLUS
CN 1,4-Benzenedicarboxamide, N1-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-05-3 HCAPLUS
CN 4-Isoxazolecarboxamide, 5-methyl-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-06-4 HCAPLUS
CN Benzamide, 4-cyano-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-07-5 HCAPLUS
CN 4-Pyridinecarboxamide, N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-08-6 HCAPLUS
CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 851318-10-0 HCAPLUS
CN Carbamic acid, [2-methyl-5-[[(2-methylpropoxy)carbonyl]amino]phenyl][5-(3-pyridinyl)-2-oxazolyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 851318-11-1 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 851318-12-2 HCAPLUS
CN Benzeneacetamide, 4-methyl-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-13-3 HCAPLUS
CN Benzeneacetamide, 4-fluoro-N-[4-methoxy-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-14-4 HCAPLUS
CN Benzeneacetamide, 2,4-difluoro-N-[4-methyl-3-[(5-phenyl-2-oxazolyl)amino]phenyl]- (CA INDEX NAME)



RN 851318-15-5 HCAPLUS
CN Benzeneacetamide, 3-bromo-N-[4-methyl-3-[[5-(2-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-16-6 HCAPLUS
CN Benzenepropanamide, 4-fluoro-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-17-7 HCAPLUS
CN Benzeneacetamide, 4-fluoro-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-18-8 HCAPLUS
CN Benzeneacetamide, N-[3-[[5-(4-cyanophenyl)-2-oxazolyl]amino]-4-methylphenyl]-2,4-difluoro- (CA INDEX NAME)



RN 851318-19-9 HCAPLUS
CN Pentanamide, 4-methyl-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-21-3 HCAPLUS
CN 1-Piperazinepropanamide, N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-22-4 HCAPLUS
CN Benzeneacetamide, 2,6-dichloro-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-23-5 HCAPLUS
CN 1-Pyrrolidinepropanamide, N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-24-6 HCAPLUS
CN Benzeneacetamide, N-[4-methoxy-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 851318-25-7 HCAPLUS
CN Benzeneacetamide, 4-methoxy-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



IT 851318-39-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-(arylamino)oxazole derivs. as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3)
RN 851318-39-3 HCAPLUS
CN Acetamide, 2-chloro-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:2836 HCAPLUS
DOCUMENT NUMBER: 140:77135
TITLE: Preparation of oxazolylureidoanilines as inhibitors of serine proteases such as Factor VIIa.
INVENTOR(S): Slusasrchyk, William A.; Bolton, Scott A.; Herpin, Timothy; Bisacchi, Gregory S.; Pi, Zulan; Priestley, E. Scott
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000788	A1	20031231	WO 2003-US19605	20030617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003245614	A1	20040106	AU 2003-245614	20030617
US 20040019085	A1	20040129	US 2003-464035	20030617
US 6846838	B2	20050125		
EP 1551794	A1	20050713	EP 2003-739243	20030617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-389832P P 20020619
WO 2003-US19605 W 20030617
OTHER SOURCE(S): MARPAT 140:77135
GI



I



II

AB Title compds. [I; A = 0-1 5-6 membered (unsatd.) (substituted) carbocyclyl, heterocyclyl, heteroaryl; B = (substituted) oxazolyl, triazolyl, pyrazolyl, imidazolyl; D = (substituted) phenylene, 5-6 membered heteroaryl, heterocyclyl, cycloalkyl; R4, R5 = H, halo, OH, cyano, alkoxy, OCF3, amino, etc.; R6 = H, (substituted) alkyl; R7, R8 = H, halo, OH, cyano, alkoxy, CF3, OCF3, amino, (substituted) alkyl, etc.; R9, R10 = H, (substituted) alkyl; NR9R10 = 3-8 membered (substituted) heterocyclyl; R11 = 0-4 halo, cyano, NO2, (substituted) alkyl, alkenyl, alkynyl, etc.; R12 = H, (substituted) alkyl; R13, R14 = H, (substituted) alkyl, cyano, OH, alkoxy, cycloalkyl, heterocyclyl, etc.], were prepared as Factor VIIa inhibitors (no data). Thus, title compound (II) was prepared in 11 steps.

IT 639475-69-7P 639475-73-3P 639475-75-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolylureidoanilines as inhibitors of serine proteases such as Factor VIIa)

RN 639475-69-7 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-[(aminocarbonyl)amino]-4-(2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639475-73-3 HCAPLUS
CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[3-[[(methylamino)carbonyl]amino]-4-(2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 639475-72-2
CMF C24 H25 N7 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 639475-75-5 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-[[(ethylamino)carbonyl]amino]-4-(2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:755249 HCAPLUS
DOCUMENT NUMBER: 137:263025
TITLE: Preparation of substituted oxazoles as IMPDH inhibitors
INVENTOR(S): Liu, Chunjian; Dhar, T. G. Murali; Gu, Henry H.; Iwanowicz, Edwin J.; Leftheris, Katerina; Pitts,

William J.; Herpin, Timothy F.; Pi, Zulan; Bisacchi, Gregory S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 428,432.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020143176	A1	20021003	US 2001-997963	20011129
US 6596747	B2	20030722		
US 6399773	B1	20020604	US 1999-428432	19991027
WO 2003047512	A2	20030612	WO 2002-US38038	20021127
WO 2003047512	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002352950	A1	20030617	AU 2002-352950	20021127
EP 1448187	A2	20040825	EP 2002-789910	20021127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.:		
US 1998-106186P	P	19981029
US 1999-428432	A2	19991027
US 2001-997963	A	20011129
WO 2002-US38038	W	20021127

OTHER SOURCE(S): MARPAT 137:263025
GI



I



II

AB Title compds. I [D = mono/bicyclic (hetero)cyclic ring; A = R3, R4; R3 = 5-6-membered (un)saturated heterocyclic ring; R4 = H, halo, NO, CF3, alkyl, alkoxy, etc.; R = H, alkyl; R1-2 = H, halo, NO2, alkyl, etc.; B = mono/bicyclic (hetero)cyclic ring system] were prepared 5-(4-Amino-2-methoxyphenyl)oxazole was reacted with di-Ph cyanocarbonimidate (CH3CN, reflux, 40 h) to give an intermediate which was reacted with 2-hydrazinopyridine to afford II. I are effective inhibitors of IMPDH enzyme and/or serine protease factor VIIa.

IT 463941-52-8P, N-[2-[2-((3-Acetylaminophenyl)amino)oxazol-5-yl]benzyl]-2-amino-N-methylacetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(IMPDH inhibitor; preparation of substituted oxazoles as IMPDH inhibitors)

RN 463941-52-8 HCAPLUS

CN Acetamide, N-[[2-[2-[[3-(acetylamino)phenyl]amino]-5-oxazolyl]phenyl]methyl]-2-amino-N-methyl- (CA INDEX NAME)



=> d l11 ibib abs tot

L11 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:259908 HCAPLUS
DOCUMENT NUMBER: 146:309313
TITLE: Use of aminoarylthiazole and aminoaryloxazole dual c-kit/FGFR3 inhibitors for treating multiple myeloma
INVENTOR(S): Moussy, Alain; Kinet, Jean-Pierre
PATENT ASSIGNEE(S): Ab Science, Fr.
SOURCE: PCT Int. Appl., 31pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007026251	A2	20070308	WO 2006-IB3111	20060713
WO 2007026251	A3	20070712		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1904065	A2	20080402	EP 2006-820848	20060713
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20080207572	A1	20080828	US 2008-995592	20080114
PRIORITY APPLN. INFO.:			US 2005-698937P P	20050714
			WO 2006-IB3111 W	20060713

OTHER SOURCE(S): MARPAT 146:309313
AB The invention relates to a method for treating Multiple Myeloma, FGFR3+ myeloma, especially relapsed or refractory multiple myeloma (4/14) expressing FGFR3, comprising administering a dual c-kit/FGFR3 inhibitor, e.g. 2-aminoarylthiazoles and 2-aminoaryloxazoles.

L11 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:395287 HCAPLUS
DOCUMENT NUMBER: 142:447205
TITLE: Preparation of 2-(arylamino)oxazole derivatives as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3
INVENTOR(S): Moussy, Alain; Wermuth, Camille; Grierson, David; Benjahad, Abdellah; Croisy, Martine; Ciufolini, Marco; Giethlen, Bruno
PATENT ASSIGNEE(S): Science AB, Fr.; Centre National de la Recherche Scientifique CNRS; Institut Curie
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040139	A2	20050506	WO 2004-IB3698	20041022
WO 2005040139	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004283162	A1	20050506	AU 2004-283162	20041022
CA 2542909	A1	20050506	CA 2004-2542909	20041022
EP 1684750	A2	20060802	EP 2004-791783	20041022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015467	A	20061219	BR 2004-15467	20041022
JP 2007509130	T	20070412	JP 2006-536215	20041022
CN 1950347	A	20070418	CN 2004-80037159	20041022
US 20070142390	A1	20070621	US 2006-576267	20060418
IN 2006DN02206	A	20070420	IN 2006-DN2206	20060421
MX 2006004581	A	20061120	MX 2006-4581	20060424
NO 2006002308	A	20060522	NO 2006-2308	20060522
KR 2006118500	A	20061123	KR 2006-710034	20060523
PRIORITY APPLN. INFO.:			US 2003-513214P P	20031023
			WO 2004-IB3698 W	20041022

OTHER SOURCE(S): CASREACT 142:447205; MARPAT 142:447205
GI



I



II

AB Title compds. I [R1, R2, R3, and R4 independently = H, halo, alkyloxy, etc.; R5 = H, (un)substituted linear or branched alkyl, COR8, etc.; R6 and R7 independently = H, halo, (un)substituted aryl, etc.; R8 = (un)substituted-aryl, -alkyl, -heteroaryl, etc.; R9 and/or R10 = H, (un)substituted-alkyl, -aryl, etc.; X = (un)substituted-alkyl, C:OY, NR9R10, etc.; Y = NR9R10, NHR9R10, (un)substituted-aryl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors. Thus, e.g., 3-acetyl-pyridine was brominated and subsequently converted into the azido derivative, which was cyclized with 2-methyl-5-nitrophenyl isocyanate followed by a reduction to the resp. amine derivative, which could be further elaborated to give II. The activity of I was evaluated in tyrosine kinase inhibition assays and it revealed that selected compds. of the invention possessed IC50 values of less than 1 μM. I should prove useful in the treatment of neoplastic diseases. Pharmaceutical compns. comprising I are disclosed.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:2836 HCAPLUS
DOCUMENT NUMBER: 140:77135
TITLE: Preparation of oxazolylureidoanilines as inhibitors of serine proteases such as Factor VIIa.
INVENTOR(S): Slusasrchyk, William A.; Bolton, Scott A.; Herpin, Timothy; Bisacchi, Gregory S.; Pi, Zulan; Priestley, E. Scott
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000788	A1	20031231	WO 2003-US19605	20030617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003245614	A1	20040106	AU 2003-245614	20030617
US 20040019085	A1	20040129	US 2003-464035	20030617
US 6846838	B2	20050125		
EP 1551794	A1	20050713	EP 2003-739243	20030617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-389832P	P 20020619
			WO 2003-US19605	W 20030617

OTHER SOURCE(S): MARPAT 140:77135

GI



I



II

AB Title compds. [I; A = 0-1 5-6 membered (unsatd.) (substituted) carbocyclyl, heterocyclyl, heteroaryl; B = (substituted) oxazolyl, triazolyl, pyrazolyl, imidazolyl; D = (substituted) phenylene, 5-6 membered heteroaryl, heterocyclyl, cycloalkyl; R4, R5 = H, halo, OH, cyano, alkoxy, OCF3, amino, etc.; R6 = H, (substituted) alkyl; R7, R8 = H, halo, OH, cyano, alkoxy, CF3, OCF3, amino, (substituted) alkyl, etc.; R9, R10 = H, (substituted) alkyl; NR9R10 = 3-8 membered (substituted) heterocyclyl; R11 = 0-4 halo, cyano, NO2, (substituted) alkyl, alkenyl, alkynyl, etc.; R12 = H, (substituted) alkyl; R13, R14 = H, (substituted)

alkyl, cyano, OH, alkoxy, cycloalkyl, heterocyclyl, etc.], were prepared as Factor VIIa inhibitors (no data). Thus, title compound (II) was prepared in 11 steps.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:755249 HCAPLUS
DOCUMENT NUMBER: 137:263025
TITLE: Preparation of substituted oxazoles as IMPDH inhibitors
INVENTOR(S): Liu, Chunjian; Dhar, T. G. Murali; Gu, Henry H.; Iwanowicz, Edwin J.; Leftheris, Katerina; Pitts, William J.; Herpin, Timothy F.; Pi, Zulan; Bisacchi, Gregory S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 428,432.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020143176	A1	20021003	US 2001-997963	20011129
US 6596747	B2	20030722		
US 6399773	B1	20020604	US 1999-428432	19991027
WO 2003047512	A2	20030612	WO 2002-US38038	20021127
WO 2003047512	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002352950	A1	20030617	AU 2002-352950	20021127
EP 1448187	A2	20040825	EP 2002-789910	20021127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.:
US 1998-106186P P 19981029
US 1999-428432 A2 19991027
US 2001-997963 A 20011129
WO 2002-US38038 W 20021127

OTHER SOURCE(S): MARPAT 137:263025
GI



I



II

AB Title compds. I [D = mono/bicyclic (hetero)cyclic ring; A = R3, R4; R3 = 5-6-membered (un)saturated heterocyclic ring; R4 = H, halo, NO, CF3, alkyl, alkoxy, etc.; R = H, alkyl; R1-2 = H, halo, NO2, alkyl, etc.; B = mono/bicyclic (hetero)cyclic ring system] were prepared 5-(4-Amino-2-methoxyphenyl)oxazole was reacted with di-Ph cyanocarbonimidate (CH3CN, reflux, 40 h) to give an intermediate which was reacted with 2-hydrazinopyridine to afford II. I are effective inhibitors of IMPDH enzyme and/or serine protease factor VIIa.

=> d his

(FILE 'HOME' ENTERED AT 11:44:01 ON 02 FEB 2009)

FILE 'REGISTRY' ENTERED AT 11:44:15 ON 02 FEB 2009
L1 STRUCTURE UPLOADED
L2 38 S L1
L3 675 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 11:44:51 ON 02 FEB 2009
L4 43 S L3

FILE 'REGISTRY' ENTERED AT 11:47:30 ON 02 FEB 2009
L5 STRUCTURE UPLOADED
L6 3 S L5
L7 62 S L5 SSS FULL
L8 STRUCTURE UPLOADED
L9 0 S L8
L10 3 S L8 SSS FULL

FILE 'HCAPLUS' ENTERED AT 11:50:10 ON 02 FEB 2009
L11 4 S L7
L12 4 S L10

```
=> s 14 and py<=2003
     24034228 PY<=2003
L13          20 L4 AND PY<=2003

=> s l13 and p/dt
      6538018 P/DT
L14          11 L13 AND P/DT

=> s l14 and us/pc
      1892403 US/PC
L15           8 L14 AND US/PC

=> d l15 ibib abs hitstr tot

L15  ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2004:2836  HCAPLUS
DOCUMENT NUMBER:          140:77135
TITLE:                    Preparation of oxazolylureidoanilines as inhibitors of
                          serine proteases such as Factor VIIa.
INVENTOR(S):              Slusasrchyk, William A.; Bolton, Scott A.; Herpin,
                          Timothy; Bisacchi, Gregory S.; Pi, Zulan; Priestley,
                          E. Scott
PATENT ASSIGNEE(S):       Bristol-Myers Squibb Company, USA
SOURCE:                   PCT Int. Appl., 55 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.         DATE
     --------------        ----   --------    -------------------     --------
     WO 2004000788          A1    20031231    WO 2003-US19605         20030617 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR,
             TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003245614          A1    20040106    AU 2003-245614          20030617
     US 20040019085         A1    20040129    US 2003-464035          20030617 <--
     US 6846838             B2    20050125
     EP 1551794             A1    20050713    EP 2003-739243          20030617
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.:                       US 2002-389832P     P  20020619
                                             WO 2003-US19605     W  20030617

OTHER SOURCE(S):          MARPAT 140:77135
GI
```



I



II

AB Title compds. [I; A = 0-1 5-6 membered (unsatd.) (substituted) carbocyclyl, heterocyclyl, heteroaryl; B = (substituted) oxazolyl, triazolyl, pyrazolyl, imidazolyl; D = (substituted) phenylene, 5-6 membered heteroaryl, heterocyclyl, cycloalkyl; R4, R5 = H, halo, OH, cyano, alkoxy, OCF3, amino, etc.; R6 = H, (substituted) alkyl; R7, R8 = H, halo, OH, cyano, alkoxy, CF3, OCF3, amino, (substituted) alkyl, etc.; R9, R10 = H, (substituted) alkyl; NR9R10 = 3-8 membered (substituted) heterocyclyl; R11 = 0-4 halo, cyano, NO2, (substituted) alkyl, alkenyl, alkynyl, etc.; R12 = H, (substituted) alkyl; R13, R14 = H, (substituted) alkyl, cyano, OH, alkoxy, cycloalkyl, heterocyclyl, etc.], were prepared as Factor VIIa inhibitors (no data). Thus, title compound (II) was prepared in 11 steps.

IT 639475-69-7P 639475-73-3P 639475-75-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolylureidoanilines as inhibitors of serine proteases such as Factor VIIa)

RN 639475-69-7 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[3-[(aminocarbonyl)amino]-4-(2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639475-73-3 HCAPLUS

CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[3-[[(methylamino)carbonyl]amino]-4-(2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 639475-72-2
CMF C24 H25 N7 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 639475-75-5 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-[[(ethylamino)carbonyl]amino]-4-(2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



IT 639475-88-0P 639475-91-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolylureidoanilines as inhibitors of serine proteases

such as Factor VIIa)
RN 639475-88-0 HCAPLUS
CN Benzoic acid, 5-[[5-[2-[[[2-[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]methylamino]methyl]phenyl]-2-oxazolyl]amino]-2-(2-oxazolyl)-, methyl ester (CA INDEX NAME)



RN 639475-91-5 HCAPLUS
CN Benzoic acid, 5-[[5-[2-[[[2-[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]methylamino]methyl]phenyl]-2-oxazolyl]amino]-2-(2-oxazolyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:2622 HCAPLUS
DOCUMENT NUMBER: 140:53429
TITLE: Use of compounds having an amine nucleus in manufacture of a medicament useful for treating factor VIIa-associated conditions
INVENTOR(S): Herpin, Timothy; Bisacchi, Gregory S.; Pi, Zulan; Priestley, E. Scott; Dhar, T. G. Murali
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2004000214	A2	20031231	WO 2003-US19155	20030617 <--
WO 2004000214	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003279182	A1	20040106	AU 2003-279182	20030617
US 20040029940	A1	20040212	US 2003-464366	20030617 <--
US 7041692	B2	20060509		
EP 1532103	A2	20050525	EP 2003-742043	20030617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060173057	A1	20060803	US 2006-377104	20060316 <--
PRIORITY APPLN. INFO.:			US 2002-389833P	P 20020619
			US 2003-464366	A3 20030617
			WO 2003-US19155	W 20030617

OTHER SOURCE(S): MARPAT 140:53429

AB Use of at least one compound having an amine nucleus, or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in the manufacture of a medicament useful for treating conditions associated with the activity of Factor VIIa is described.

IT 1027167-49-2
RL: PRPH (Prophetic)
(Use of compounds having an amine nucleus in manufacture of a medicament useful for treating factor VIIa-associated conditions)

RN 1027167-49-2 HCAPLUS

CN Acetamide, N-[[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl-2-(methylamino)- (CA INDEX NAME)



IT 639458-85-8P 639458-89-2P 639458-94-9P
639458-95-0P 639459-05-5P 639459-06-6P
639459-07-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(use of compds. for treating factor VIIa-associated conditions)

RN 639458-85-8 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639458-89-2 HCAPLUS
CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[3-(phenylmethoxy)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (CA INDEX NAME)



RN 639458-94-9 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[(2-methoxy[1,1'-biphenyl]-4-yl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639458-95-0 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-chloro-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-05-5 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-chloro-4-(2-thiazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-06-6 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-ethyl-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-07-7 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



IT 639459-18-0 639459-19-1 639459-20-4
639459-21-5 639459-22-6 639459-23-7
639459-24-8 639459-25-9 639459-26-0
639459-27-1 639459-28-2 639459-29-3
639459-30-6 639459-31-7 639459-32-8
639459-33-9 639459-34-0 639459-35-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of compds. for treating factor VIIa-associated conditions)
RN 639459-18-0 HCAPLUS
CN Acetamide, 2-amino-N-[[5-fluoro-2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-19-1 HCAPLUS
CN Acetamide, 2-amino-N-[1-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]ethyl]-N-methyl- (CA INDEX NAME)



RN 639459-20-4 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[4-(4-ethyl-4,5-dihydro-2-oxazolyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-21-5 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[4-(4,5-dihydro-4-methyl-2-oxazolyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-22-6 HCAPLUS
CN Acetamide, 2-amino-N-[[5-chloro-2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-23-7 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[4-(4-ethyl-2-oxazolyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-24-8 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(4-methyl-2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-25-9 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[4-(3-furanyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-26-0 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(2-methyl-5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-27-1 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(5-methyl-2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-28-2 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[(4-cyano-3-methoxyphenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-29-3 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[(4-bromo-3-methoxyphenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-30-6 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(2-methyl-1-propen-1-yl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-31-7 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[4-[(hydroxyamino)iminomethyl]-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-32-8 HCAPLUS
CN Acetamide, 2-amino-N-ethyl-N-[[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (CA INDEX NAME)



RN 639459-33-9 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (CA INDEX NAME)



RN 639459-34-0 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[4-(2-furanyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-35-1 HCAPLUS
CN Cyclopentanecarboxamide, 1-amino-N-[[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:755249 HCAPLUS
DOCUMENT NUMBER: 137:263025
TITLE: Preparation of substituted oxazoles as IMPDH inhibitors
INVENTOR(S): Liu, Chunjian; Dhar, T. G. Murali; Gu, Henry H.; Iwanowicz, Edwin J.; Leftheris, Katerina; Pitts, William J.; Herpin, Timothy F.; Pi, Zulan; Bisacchi, Gregory S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 428,432.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020143176	A1	20021003	US 2001-997963	20011129 <--

US 6596747	B2	20030722			
US 6399773	B1	20020604	US 1999-428432	19991027	<--
WO 2003047512	A2	20030612	WO 2002-US38038	20021127	<--
WO 2003047512	A3	20031016			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002352950	A1	20030617	AU 2002-352950	20021127	<--
EP 1448187	A2	20040825	EP 2002-789910	20021127	

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRIORITY APPLN. INFO.:	US 1998-106186P	P 19981029
	US 1999-428432	A2 19991027
	US 2001-997963	A 20011129
	WO 2002-US38038	W 20021127

OTHER SOURCE(S): MARPAT 137:263025

GI



I



II

AB Title compds. I [D = mono/bicyclic (hetero)cyclic ring; A = R3, R4; R3 = 5-6-membered (un)saturated heterocyclic ring; R4 = H, halo, NO, CF3, alkyl, alkoxy, etc.; R = H, alkyl; R1-2 = H, halo, NO2, alkyl, etc.; B = mono/bicyclic (hetero)cyclic ring system] were prepared 5-(4-Amino-2-methoxyphenyl)oxazole was reacted with di-Ph cyanocarbonimidate (CH3CN, reflux, 40 h) to give an intermediate which was reacted with 2-hydrazinopyridine to afford II. I are effective inhibitors of IMPDH enzyme and/or serine protease factor VIIa.

IT 267645-41-0P, 2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-(2-

pyridinyl)oxazole 267645-42-1P,
2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-(tetrahydro-2-furanyl)oxazole
267645-48-7P, 5-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-[[3-methoxy-4-
(5-oxazolyl)phenyl]amino]oxazole 267645-67-0P,
5-(2-Furanyl)-2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxazole
267645-68-1P, 2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-
oxazolyl]-1-pyrrolidinecarboxylic acid phenylmethyl ester
267645-93-2P, 2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-(2-
pyrrolidinyl)oxazole 267645-94-3P,
2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-1-
pyrrolidinecarboxylic acid Methyl Ester 267645-95-4P,
2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-N-
methoxymethylcarbonylpyrrolidine 267645-96-5P,
2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-N-
(((morpholino)methyl)carbonyl)pyrrolidine 267645-98-7P,
2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-1-
pyrrolidinecarboxylic acid 2-(methylsulfonyl)ethyl ester
267645-99-8P 267647-75-6P,
2-[(3-Methoxy-4-cyanophenyl)amino]-5-phenyloxazole 463941-28-8P,
2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-1-
pyrrolidinecarboxylic acid ethyl ester 463941-31-3P,
2-Amino-N-[2-[2-(3-methoxy-4-methylphenylamino)oxazol-5-yl]benzyl]-N-
methylacetamide 463941-36-8P,
2-Amino-N-[2-[2-(3-methoxyphenylamino)oxazol-5-yl]benzyl]-N-
methylacetamide 463941-38-0P,
2-Amino-N-[2-[2-(3-chlorophenylamino)oxazol-5-yl]benzyl]-N-methylacetamide
463941-42-6P, 2-Amino-N-[2-[2-(3,4-dichlorophenylamino)oxazol-5-
yl]benzyl]-N-methylacetamide 463941-43-7P,
2-Amino-N-[2-[2-(3-cyanophenylamino)oxazol-5-yl]benzyl]-N-methylacetamide
463941-49-3P, 2-Amino-N-methyl-N-[2-[2-(3-nitrophenylamino)oxazol-
5-yl]benzyl]acetamide 463941-52-8P,
N-[2-[2-((3-Acetylaminophenyl)amino)oxazol-5-yl]benzyl]-2-amino-N-
methylacetamide 463941-53-9P,
3-[[5-[2-[[(2-Aminoacetyl)methylamino]methyl]phenyl]oxazol-2-yl]amino]-N-
methylbenzamide 463941-55-1P,
4-[[5-[2-[[(2-Aminoacetyl)methylamino]methyl]phenyl]oxazol-2-yl]amino]-2-
methoxybenzoic acid methyl ester 463941-57-3P
463941-64-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(IMPDH inhibitor; preparation of substituted oxazoles as IMPDH inhibitors)

RN 267645-41-0 HCAPLUS

CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(2-pyridinyl)- (CA INDEX NAME)



RN 267645-42-1 HCAPLUS

CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(tetrahydro-2-furanyl)-
(CA INDEX NAME)



RN 267645-48-7 HCAPLUS
CN 2-Oxazolamine, 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[3-methoxy-4-(5-
oxazolyl)phenyl]- (CA INDEX NAME)



RN 267645-67-0 HCAPLUS
CN 2-Oxazolamine, 5-(2-furanyl)-N-[3-methoxy-4-(5-oxazolyl)phenyl]- (CA
INDEX NAME)



RN 267645-68-1 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-
5-oxazolyl]-, phenylmethyl ester (CA INDEX NAME)



RN 267645-93-2 HCAPLUS
CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(2-pyrrolidinyl)- (CA
INDEX NAME)



RN 267645-94-3 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, methyl ester (CA INDEX NAME)



RN 267645-95-4 HCAPLUS
CN Ethanone, 2-methoxy-1-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-1-pyrrolidinyl]- (CA INDEX NAME)



RN 267645-96-5 HCAPLUS
CN Ethanone, 1-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-1-pyrrolidinyl]-2-(4-morpholinyl)- (CA INDEX NAME)



RN 267645-98-7 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, 2-(methylsulfonyl)ethyl ester (CA INDEX NAME)



RN 267645-99-8 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, tetrahydro-3-furanyl ester (CA INDEX NAME)



RN 267647-75-6 HCAPLUS
CN Benzonitrile, 2-methoxy-4-[(5-phenyl-2-oxazolyl)amino]- (CA INDEX NAME)



RN 463941-28-8 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, ethyl ester (CA INDEX NAME)



RN 463941-31-3 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[(3-methoxy-4-methylphenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 463941-36-8 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[(3-methoxyphenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 463941-38-0 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[(3-chlorophenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 463941-42-6 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[(3,4-dichlorophenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 463941-43-7 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[(3-cyanophenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 463941-49-3 HCAPLUS
CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[(3-nitrophenyl)amino]-5-oxazolyl]phenyl]methyl]- (CA INDEX NAME)



RN 463941-52-8 HCAPLUS
CN Acetamide, N-[[2-[2-[[3-(acetylamino)phenyl]amino]-5-oxazolyl]phenyl]methyl]-2-amino-N-methyl- (CA INDEX NAME)



RN 463941-53-9 HCAPLUS
CN Benzamide, 3-[[5-[2-[[(3-amino-2-oxopropyl)amino]methyl]phenyl]-2-oxazolyl]amino]-N-methyl- (CA INDEX NAME)



RN 463941-55-1 HCAPLUS
CN Benzoic acid, 4-[[5-[2-[[(3-amino-2-oxopropyl)amino]methyl]phenyl]-2-oxazolyl]amino]-2-methoxy-, methyl ester (CA INDEX NAME)



RN 463941-57-3 HCAPLUS
CN Acetamide, 2-amino-N-[[3-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-4-pyridinyl]methyl]-N-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 463941-56-2
CMF C22 H22 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 463941-64-2 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-3-pyridinyl]methyl]-N-methyl- (CA INDEX NAME)



IT 463941-62-0P 463941-63-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of substituted oxazoles as IMPDH inhibitors)
RN 463941-62-0 HCAPLUS
CN Carbamic acid, [[3-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-4-pyridinyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 463941-63-1 HCAPLUS
CN 4-Pyridinemethanamine, 3-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-N-methyl- (CA INDEX NAME)



L15 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:479495 HCAPLUS
DOCUMENT NUMBER: 129:108995
ORIGINAL REFERENCE NO.: 129:22397a,22400a
TITLE: Preparation of aromatic and heterocyclic amine derivatives as NOS inhibitors
INVENTOR(S): Esaki, Toru; Makino, Toshihiko; Nishimura, Yoshikazu; Nagafuji, Toshiaki
PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9828257	A1	19980702	WO 1997-JP4762	19971224 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, GW, HU, ID, IL, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,				

FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2275933	A1	19980702	CA 1997-2275933		19971224 <--
AU 9853394	A	19980717	AU 1998-53394		19971224 <--
AU 742388	B2	20020103			
JP 10237028	A	19980908	JP 1997-366474		19971224 <--
EP 949242	A1	19991013	EP 1997-950368		19971224 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
HU 2000000321	A2	20000828	HU 2000-321		19971224 <--
HU 2000000321	A3	20000928			
RU 2193554	C2	20021127	RU 1999-116598		19971224 <--
TW 584622	B	20040421	TW 1997-86119687		19971224
NO 9903109	A	19990824	NO 1999-3109		19990622 <--
US 6331553	B1	20011218	US 1999-331733		19990624 <--
PRIORITY APPLN. INFO.:			JP 1996-359791	A	19961224
			WO 1997-JP4762	W	19971224

OTHER SOURCE(S): MARPAT 129:108995

GI



I



II

AB The title compds. I [R1 and R2 represent each hydrogen, etc.; R3 and R4 represent each hydrogen, lower alkyl, etc.; R5 represents hydrogen, etc.; X1, X2, X3 and X4 represent each hydrogen, lower alkoxyl, etc.; A represents an optionally substituted pyridine ring, etc.; and m and n are each 0 or 1] are prepared I are useful as pharmaceuticals for cerebrovascular disorders, etc. The title compound II in vitro showed IC50 values of 22.6 nM and 916.7 nM against nNOS and iNOS, resp.

IT 209898-14-6P 209898-16-8P 209898-18-0P
209898-20-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic and heterocyclic amine derivs. as NOS inhibitors)

RN 209898-14-6 HCAPLUS
CN 2-Oxazolamine, N-[3-(aminomethyl)phenyl]-5-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 209898-13-5
CMF C11 H13 N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 209898-16-8 HCAPLUS
CN 2-Oxazolamine, N-[3-(aminomethyl)-2-ethoxyphenyl]-5-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 209898-15-7
CMF C13 H17 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 209898-18-0 HCAPLUS
CN 2-Oxazolamine, N-[3-(aminomethyl)-2-methylphenyl]-5-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 209898-17-9
CMF C12 H15 N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 209898-20-4 HCAPLUS
CN 2-Oxazolamine, N-[3-(aminomethyl)-4-methoxyphenyl]-5-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 209898-19-1
CMF C12 H15 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 209899-15-0P 209899-17-2P 209899-18-3P
209899-19-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aromatic and heterocyclic amine derivs. as NOS inhibitors)
RN 209899-15-0 HCAPLUS
CN Imidodicarbonic acid, N-[[3-[(5-methyl-2-oxazolyl)amino]phenyl]methyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 209899-17-2 HCAPLUS
CN Imidodicarbonic acid, N-[[2-ethoxy-3-[(5-methyl-2-oxazolyl)amino]phenyl]methyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 209899-18-3 HCAPLUS
CN Imidodicarbonic acid, N-[[2-methyl-3-[(5-methyl-2-oxazolyl)amino]phenyl]methyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 209899-19-4 HCAPLUS
CN Imidodicarbonic acid, N-[[2-methoxy-5-[(5-methyl-2-oxazolyl)amino]phenyl]methyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



REFERENCE COUNT: 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:640645 HCAPLUS
DOCUMENT NUMBER: 127:278199
ORIGINAL REFERENCE NO.: 127:54337a,54340a
TITLE: Preparation of 2,4-diaminopyridine derivatives as

antagonists of neuropeptide Y receptors
INVENTOR(S): Fukami, Takehiro; Mase, Toshiaki; Tsuchiya, Yoshimi; Kanatani, Akio; Fukuroda, Takahiro
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan; Fukami, Takehiro; Mase, Toshiaki; Tsuchiya, Yoshimi; Kanatani, Akio; Fukuroda, Takahiro
SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9734873	A1	19970925	WO 1997-JP890	19970319 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2249222	A1	19970925	CA 1997-2249222	19970319 <--
CA 2249222	C	20051108		
AU 9720428	A	19971010	AU 1997-20428	19970319 <--
EP 889034	A1	19990107	EP 1997-908495	19970319 <--
EP 889034	B1	20030917		
R: DE, FR, GB, IT				
JP 4106711	B2	20080625	JP 1997-533359	19970319
US 6011039	A	20000104	US 1998-142162	19981013 <--

PRIORITY APPLN. INFO.: JP 1996-91968 A 19960321
WO 1997-JP890 W 19970319

GI



I

AB Compds. of general formula [I; Ar1 = aryl or heteroaryl which may be substituted with a radical selected from the group consisting of lower alkyl, lower hydroxyalkyl, lower alkylene and NRaRb; wherein Ra, Rb = hydrogen or lower alkyl; R2, R3 = lower alkyl or alternatively R2 and R3 are united to form alkylene which may be interrupted by oxygen or sulfur and may be substituted with one or two lower alkyl radicals; R4 = hydrogen or lower alkyl which may be substituted with a radical selected from the

group consisting of hydroxyl, amino, carbamoyl, and lower alkoxycarbonyl; Ar2 = aryl or heteroaryl which may be substituted with a radical selected from the group consisting of halogeno, hydroxyl, lower alkyl, lower haloalkyl, lower alkoxy, lower alkylthio, lower hydroxyalkyl, lower alkoxy lower alkyl, NRcRd, and NReCONRfRg; wherein Rc = hydrogen or lower alkyl; Rd = hydrogen, lower alkyl, CORh, SO2Ri, optionally substituted heterocyclyl; Re, Rf = hydrogen, lower alkyl or alkenyl, optionally substituted aryl or heteroaryl; Rh = lower alkyl or alkoxy, lower alkoxy-lower alkoxy, lower alkenyloxy or alkynyloxy, heterocyclyl-C1-3 n-alkoxy; Ri = lower alkyl or alkenyl; W = oxygen, sulfur, CHRj, or NRk; Rj, Rk = H, lower alkyl] or pharmaceutically acceptable salts thereof are prepared Agents for the treatment of hyperphagia, obesity or diabetes comprising I the active ingredients are claimed. Thus, 2-[N-tert-butoxycarbonyl-N-(3-carboxybenzyl)amino]-6-(5-ethyl-1,3,4-thiadiazol-2-ylthiomethyl)-4-morpholinopyridine (preparation given) was refluxed with (PhO)2P(O)N3, allyl alc., and Et3N in DMF for 3 h, followed by treatment with CF3CO2H to give the title compound (II). II in vitro showed IC50 of 0.33 nM for inhibiting the binding of [125I]peptide YY to membrane preparation from human neuroblastoma SKN-MC cells.

IT 196498-35-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaminopyridine derivs. as antagonists of neuropeptide Y receptors for treatment of hyperphagia, obesity, or diabetes)

RN 196498-35-8 HCAPLUS

CN 2-Pyridinamine, 6-[[(5-ethyl-1,3,4-thiadiazol-2-yl)thio]methyl]-N-[[3-[(4-methyl-2-oxazolyl)amino]phenyl]methyl]-4-(4-morpholinyl)- (CA INDEX NAME)



IT 196500-06-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of diaminopyridine derivs. as antagonists of neuropeptide Y receptors for treatment of hyperphagia, obesity, or diabetes)

RN 196500-06-8 HCAPLUS

CN Carbamic acid, (4-methyl-2-oxazolyl)[3-[[(methylsulfonyl)oxy]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L15 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1991:471590 HCAPLUS
DOCUMENT NUMBER: 115:71590
ORIGINAL REFERENCE NO.: 115:12379a,12382a
TITLE: Preparation of 2-amino-4,5-disubstituted oxazoles and -thiazoles as herbicide antidotes
INVENTOR(S): Grabiak, Raymond C.; Howe, Robert K.; Lee, Len F.
PATENT ASSIGNEE(S): Monsanto Co., USA
SOURCE: U.S., 48 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5000775	A	19910319	US 1985-815102	19851231 <--

PRIORITY APPLN. INFO.: US 1985-815102 19851231
OTHER SOURCE(S): MARPAT 115:71590
GI



AB The title compds. [I; R1, R2 = H, (halo)alkyl, hydroxyalkyl, cycloalkyl, alkenyl, aryl(alkyl), etc.; R3, R4 = (hydroxy)alkyl, alkoxy(alkyl), haloalkyl, aryl(alkyl), COX, CO2R5, COSR6, CONR7R8, (un)substituted 2-oxazolyl; R5, R6 = H, (alkoxy)alkyl, agriculturally acceptable cation, aryl(alkyl); R7, R8 = H, (hydroxy)alkyl, aryl, etc.; X = halo; Z = O, S], especially effective to safen acetamide herbicides used to control grassy weeds

in sorghum and broadleaf weeds in corn, were prepared, e.g., by amination of chlorothiazoles with primary amines. Thus, a stirred mixture of Et 2-chloro-4-trifluoromethyl-5-thiazolecarboxylate and tert-butylamine was refluxed 20 h to give title compound I (R1 = H, R2 = Me3C, R3 = F3C, R4 = EtO2C, Z = S) which at 8.96 kg/ha gave 69% safening effect on sorghum when co-dispersed in soil with 2.24 kg/ha alachlor. A total of 60 I were prepared and their extensive evaluation carried out with approx. 20 herbicides. Numerous formulations containing I are given.

IT 135026-19-6P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide antidote)

RN 135026-19-6 HCAPLUS

CN 5-Oxazolecarboxylic acid, 4-(trifluoromethyl)-2-[[3-(trifluoromethyl)phenyl]amino]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1991:185568 HCAPLUS
DOCUMENT NUMBER: 114:185568
ORIGINAL REFERENCE NO.: 114:31354h,31355a
TITLE: Preparation of anti-inflammatory 4-(heterocyclylamino)phenol derivatives
INVENTOR(S): Bantick, John Raymond; Hardern, David Norman; Appleton, Richard Anthony; Dixon, John; Wilkinson, David John
PATENT ASSIGNEE(S): Fisons PLC, UK
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9014338	A1	19901129	WO 1990-GB762	19900517 <--
W: AU, FI, JP, KR, NO, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
AU 9056682	A	19901218	AU 1990-56682	19900517 <--
AU 630196	B2	19921022		
ZA 9003802	A	19910130	ZA 1990-3802	19900517 <--
EP 425650	A1	19910508	EP 1990-908298	19900517 <--

EP 425650	B1	19950809				
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE						
JP 06502384	T	19940317	JP 1990-507734		19900517	<--
JP 07116155	B	19951213				
ES 2077066	T3	19951116	ES 1990-908298		19900517	<--
RU 2049779	C1	19951210	RU 1990-4894663		19900517	<--
CA 2017169	A1	19901120	CA 1990-2017169		19900518	<--
HU 54119	A2	19910128	HU 1990-3094		19900518	<--
HU 206323	B	19921028				
DD 300544	A5	19920617	DD 1990-340830		19900518	<--
PL 164432	B1	19940729	PL 1990-285248		19900518	<--
PL 164480	B1	19940831	PL 1990-289487		19900518	<--
IL 94433	A	19950315	IL 1990-94433		19900518	<--
CZ 280637	B6	19960313	CZ 1990-2444		19900518	<--
CN 1047497	A	19901205	CN 1990-103739		19900519	<--
RO 105958	B1	19930130	RO 1990-145922		19900912	<--
NO 9100198	A	19910312	NO 1991-198		19910117	<--
US 5428044	A	19950627	US 1993-138375		19931015	<--
PRIORITY APPLN. INFO.:			GB 1989-11654	A	19890520	
			GB 1989-11655	A	19890520	
			GB 1990-3044	A	19900210	
			WO 1990-GB762	A	19900517	
			US 1991-634182	B1	19910301	
			US 1992-978041	B1	19921118	

OTHER SOURCE(S): MARPAT 114:185568

GI



I

AB The title compds. [I; R1 = C(O)YZ, SO2R10; Y = single bond, O, NH, alkylimino, CO; Z = H, alkyl, alkyl substituted by ≤1 substituents selected from OH, alkoxy, acyloxy, CO2H, alkoxycarbonyl, (un)substituted CONH2 or NH2, heterocyclyl, (un)substituted aryl, etc.; R10 = alkyl; R2, R3, R5, R6 = H, alkyl, alkoxy, halo; R4 = H, alkyl; X = (un)substituted heterocyclyl] are prepared as antiinflammatories (no data). Thus, acetylation of 2,6-dimethyl-4-nitrophenol with AcCl in CH2Cl2 containing Et3N followed by hydrogenation over PtO2 in EtOH gave 4-amino-2,6-dimethylphenyl acetate which was refluxed with 3-amino-4,5-dihydro-1-phenyl-1H-pyrazole in PhMe containing 4-MeC6H4SO3H for 8 h to give 4-(4,5-dihydro-1-phenyl-1H-pyrazol-3-yl)amino-2,6-dimethylphenyl acetate. A total of 117 I containing heterocycles, i.e., pyrazole, benzimidazole, quinoline, pyrimidine, pyrazine, oxazole, 1,2,3-triazole, pyridazine, imidazole, 1,2,4-thiadiazole, thiophene, isoxazole, 1,2,4-triazine, and 1,3,4-thiadiazole, were prepared

IT 133356-02-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as antiinflammatory)
RN 133356-02-2 HCAPLUS
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-(2-oxazolylamino)-, 1-acetate (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1988:493070 HCAPLUS
DOCUMENT NUMBER: 109:93070
ORIGINAL REFERENCE NO.: 109:15541a,15544a
TITLE: Preparation, testing, and formulation of 4-(heterocyclyamino)phenols as inflammation inhibitors
INVENTOR(S): Kanai, Kenichi; Goto, Kiyoto; Hashimoto, Kinji
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Factory, Inc., Japan
SOURCE: Eur. Pat. Appl., 71 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 254259	A2	19880127	EP 1987-110503	19870720 <--
EP 254259	A3	19891123		
R: AT, CH, DE, ES, FR, GB, IT, LI, NL, SE				
AU 8775799	A	19880128	AU 1987-75799	19870717 <--
AU 590935	B2	19891123		
DK 8703774	A	19880122	DK 1987-3774	19870720 <--
US 4868183	A	19890919	US 1987-75910	19870720 <--
JP 01025756	A	19890127	JP 1987-183099	19870721 <--
JP 06051679	B	19940706		
JP 02138265	A	19900528	JP 1988-8846	19880118 <--
JP 06067911	B	19940831		
JP 02138251	A	19900528	JP 1989-210376	19890815 <--
JP 05071590	B	19931007		
US 5059598	A	19911022	US 1989-409192	19890919 <--
PRIORITY APPLN. INFO.:			JP 1986-172431 A	19860721
			JP 1986-213660 A	19860910
			JP 1987-38595 A	19870220
			JP 1987-94199 A	19870416
			US 1987-75910 A3	19870720
			JP 1987-183099	19870721

OTHER SOURCE(S): CASREACT 109:93070; MARPAT 109:93070
GI



I

AB The title compds. [I; R2 = alkyl; R2, R3 = H, alkyl; R2R3 = (CH2)4, CH:CH:CH:CH; R4 = 5- or 6-membered (substituted heteroaryl, including pyrazine-N-oxide, pyridazine-N-oxide, and pyrimidine-N-oxide but excluding thiazolyl, isothiazoly, pyridyl, and 1,3,5-triazinyl] were prepared as lipoxygenase inhibitor and antiinflammatories. To 2,6-di-tert-butyl-1,4-benzoquinone and aminopyrazine in THF was added a suspension of TiCl4 in pyridine/dichloroethane and the mixture was refluxed to give 2,6-di-tert-butyl-1,4-pyrazinylaminophenol. The latter at 37 mg/kg orally gave a 50% reduction in carrageenan-induced paw edema in rats.

IT 114559-54-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiinflammatory)

RN 114559-54-5 HCAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-(2-oxazolylamino)- (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	108.18	678.40
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-13.12	-13.12

STN INTERNATIONAL LOGOFF AT 11:56:17 ON 02 FEB 2009